Articles tagged with Cancer Patients
The NCI-MATCH trial has released new findings on three arms of the trial, showing promise in patients with rare genetic changes. The study's results suggest that future studies could see more responses in populations with earlier-stage disease.
A new study published in JAMA found that increased follow-up testing of colorectal cancer patients does not improve survival rates. The study showed that patients who underwent surgery for colorectal cancer experienced the same five-year survival rate regardless of whether they received two or five follow-up tests.
Researchers at NCI developed a high-throughput method to identify mutations recognized by the immune system, leading to a complete response in a breast cancer patient. The treatment used tumor-infiltrating lymphocytes that specifically target tumor cell mutations, showing promise for treating common epithelial cancers.
A Phase II trial suggests that erdafitinib, an FGFR inhibitor, benefits patients with metastatic urothelial cancer harboring FGFR3 mutations. The therapy achieved a 40% overall response rate, including complete and partial responses, as well as stable disease in nearly half of patients.
A new study found that men with prostate cancer who experience urinary, bowel, or sexual dysfunction after treatment are more likely to experience emotional distress, which can lead to worsening function. The researchers emphasize the need for greater investment in psychosocial care to mitigate treatment side effects and improve qualit...
A recent study from the University of Pennsylvania School of Medicine found that rates of inherited mutations in genes other than BRCA1/2 are twice as high in breast cancer patients with a second primary cancer. The study also investigated polygenic risk scores, which were not strongly linked to an increased risk of cancer.
The article highlights conflicting guidance on opioid prescribing, potentially jeopardizing pain management for patients with cancer. Key areas of concern include CDC guideline recommendations that don't align with NCCN guidelines, and the lack of evidence for non-pharmacologic treatments to manage moderate to severe pain.
A new clinical trial is testing whether omega-3 capsules can stop bowel cancer from returning after liver surgery. The trial, funded by Yorkshire Cancer Research, involves 450 patients and investigates the effectiveness of a highly purified form of EPA.
Researchers at TGen and HCI are working together to combat bone metastatic breast cancer, a leading cause of pain and death for patients. By blocking the activity of RON kinase, they aim to prevent further damage to skeletal structures and enhance anti-tumor immunity.
A 2013 CLL patient achieved complete remission with a single CAR T cell infusion, sparking insights into the human genome and immune response that may enhance response rates. The successful treatment was linked to the specific location of the CAR gene within the patient's T cell DNA.
Supriya G. Mohile, an oncologist at the Wilmot Cancer Institute, has been named the winner of the B.J. Kennedy Award by ASCO for her work in geriatric oncology. The award recognizes her research and efforts to improve communication between doctors and older patients with cancer.
Researchers discovered a naturally occurring protein called apolipoprotein A-I binding protein (AIBP) that inhibits inflammatory response underlying chronic pain processing. A single spinal injection of AIBP alleviated chemotherapy pain in mice for two months with no side effects.
Researchers found that gut bacteria can control antitumor immune responses in the liver by regulating bile acid metabolism and NKT cell accumulation. This discovery has implications for understanding liver cancer mechanisms and potential therapeutic approaches.
A new study found that gentle stretching can reduce tumor size and improve immune response in a mouse model of breast cancer. The research suggests a link between stretching, inflammation resolution, and improved immune function.
Researchers at MD Anderson Cancer Center found that intense post-treatment surveillance does not improve detection of recurrence or overall survival in stage I, II, or III colorectal cancer. The study suggests that current guideline recommendations need to be reconsidered.
Two studies found that more frequent follow-up testing did not significantly impact mortality rates from any cause or colorectal cancer over five years. However, a related editorial suggests that current guidelines should be reevaluated in the context of these findings and potential harms associated with more frequent testing.
The Annual Report to the Nation on Cancer finds a decline in US cancer death rates among men and women of all racial and ethnic groups. Prostate cancer incidence has increased, while mortality has stabilized, with trends linked to changes in PSA screening.
Researchers developed a mouse model of luminal bladder cancer to study its therapeutic efficacy, focusing on checkpoint inhibitors and neo-antigens. The model revealed lower levels of immune cells in luminal tumors and differences in neo-antigen expression between subtypes.
A breath analysis test showed good diagnostic accuracy for esophagogastric cancer in a study of 335 patients, including those already diagnosed with the disease. The test identified abnormally regulated volatile organic compounds in the breath associated with esophagogastric cancer.
A federally funded trial found that using mobile and sensor technology reduced symptom severity in patients with head and neck cancer. The technology, called CYCORE, enabled remote monitoring of patient symptoms, allowing doctors to detect concerning symptoms early and respond more rapidly.
A study of 1,800 lung cancer screening sites found that only 1.9% of eligible heavy smokers were screened in 2016. Despite USPSTF and ASCO guidelines, low screening rates persist, with the South having the lowest rate at 1.6%. The study highlights the need for effective public service campaigns to encourage lung cancer screening.
Researchers have developed new treatment regimens that significantly boost survival rates for children and young adults with rare forms of leukemia and lymphoma, such as T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). The trial showed that 90% of patients lived at least four years after starting tre...
A meta-analysis of 20 randomised trials found that patients' sex may impact the efficacy of immunotherapy in cancer treatment. Women showed a lower survival benefit compared to men, regardless of cancer type and drug administered.
Next-generation sequencing (NGS) testing for all known lung cancer-related gene changes at diagnosis is more cost-effective and faster than testing one or a limited number of genes. This approach can save up to $2.1 million for Medicare and $250,000 for commercial insurance providers.
A randomized clinical trial found that acupuncture and cognitive behavioral therapy (CBT-I) decreased insomnia severity among cancer survivors, with CBT-I being more effective for those with mild symptoms. The study suggests that patients have more choices to manage their insomnia beyond traditional medicines.
Researchers found that patients with mutations in DNA repair genes like ATM and RB1 tend not to live as long as those without. These mutations can make tumor cells more susceptible to certain treatments, bringing potential hope for targeted therapies.
A new study published in Urologic Oncology suggests that MRI fusion biopsy is a more effective method for detecting clinically significant prostate cancer in patients with prior negative biopsies. The study analyzed data from over 700 patients and found that fusion biopsy detected 30.7% of clinically significant cancers, compared to 4....
Researchers have discovered universal antibodies that can recognize and neutralize a wide range of microorganisms, including bacteria, yeasts, and viruses. These breakthrough findings hold promise for developing new treatments for life-threatening infections, particularly in patients with weakened immune systems.
A new study examines clinical, functional, and neurophysiological outcomes in 121 long-term childhood cancer survivors. Chemotherapy-induced peripheral neuropathy can be a potentially long-lasting adverse effect of chemotherapy agents.
A new computational strategy simplifies complex cancer biomolecular data by emphasizing patient-to-patient variation in molecular signatures of cancer cells. This approach aims to provide a personalized treatment plan by analyzing the genetic makeup and impaired biological pathways of individual patients.
Researchers have developed criteria for routine genetic screening of patients with medulloblastoma, a rare and malignant tumor predominantly affecting children. This analysis of 1022 patients identified six genes frequently affected by genetic alterations, increasing cancer risk in up to 20% of the patient population.
A new study found that patients with low risk of local recurrence can safely undergo surgery alone without receiving chemoradiotherapy. This strategy could reduce the number of patients who receive chemoradiotherapy by half, with minimal risk of undertreatment.
A daily tablet has been shown to significantly reduce the risk of blood clots in cancer patients, with a lower rate of recurrence compared to traditional anticoagulant treatment. The study also found increased bleeding risks with the oral drug rivaroxaban.
Researchers developed a method to identify men with locally advanced prostate cancer who are less likely to respond well to radiotherapy. A 28-gene signature accurately identifies hypoxic tumour tissue in patients with prostate cancer that invades nearby structures. This signature could lead to improved treatment outcomes for patients.
A survey of over 200 oncologists reveals that most have discussed medical marijuana use with patients, but many lack knowledge on its effectiveness. The study highlights the need for clinical trials and education to inform cancer care.
A new AI method developed by MD Anderson researchers uses deep neural networks to automate the contouring of high-risk clinical target volumes in head and neck cancers. The model achieves comparable results to trained oncologists, offering a potential solution to reduce inter-physician variability and improve treatment efficiency.
A new phase 1 trial has shown that CAR T therapy CYAD-01 can induce a complete remission in a patient with acute myeloid leukemia, lasting nine months. This breakthrough is significant as it is the first time CAR T therapy has been effective without preconditioning chemotherapy.
Researchers have identified six genes associated with an increased risk of developing medulloblastoma, a common childhood brain tumor. Genetic screening guidelines have been developed to help patients understand their lifetime cancer risk and manage their care.
A new quality-control test developed by TGen can detect cancer in blood with high accuracy, filtering out contaminants and evaluating cfDNA samples. This test has shown promising results in several cancer types, including melanoma and breast cancer.
A randomized clinical trial found that flushing the bladder with a chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning. The study, published in JAMA, showed a 34% reduction in the risk of recurrence for patients receiving the treatment.
The center aims to study ways to reduce cancer risk among underserved individuals and improve outcomes among those with a diagnosis, utilizing tools like mobile health technology.
Cancer remains a significant concern as the HIV-infected population ages. By 2030, prostate and lung cancers are projected to be the most common cancers among individuals with HIV, due to their weakened immune systems.
A new study suggests that shifting cancer diagnosis from emergency hospital admissions to GP referrals could save thousands of lives and £2,130 per life saved. The shift would come at a small additional cost to the NHS.
Pancreatic cancer researchers and clinicians will work together to build a state-wide biobank, collecting data from diverse patient groups to minimize disparities and personalize care. The goal is to develop more effective therapeutic strategies tailored to individual needs, improving survival rates and quality of life.
The GlobalSurg3 study will pool data from hundreds of hospitals worldwide to compare surgery quality and highlight ways to improve patient care. The initiative aims to provide high-quality surgical care to millions of patients diagnosed with breast, gastric, or colon cancer annually.
Early intervention after completed clinical staging leads to increased survival rates in non-small cell lung cancer patients. Surgery within eight weeks from diagnosis significantly improves overall survival.
A study by Dana-Farber Cancer Institute and Broad Institute identified five genetic subtypes of diffuse large B cell lymphoma, which can help predict individual patient outcomes and guide personalized treatment. The analysis revealed clear links between specific genetic signatures and how patients respond to standard treatment.
A multi-center study discovered how adenosine to inosine (A-to-I) RNA editing contributes to protein diversity in breast cancer, increasing cancer cell proliferation and invasion. The findings suggest that individualizing therapies for each patient is reliant upon a better understanding of the protein genome.
A new review by Boston University School of Public Health researchers found that less than one-fifth of participants in cancer-related clinical trials are obese. Obesity was associated with an increased risk of progression, recurrence, and death for specific cancer types.
Researchers at University of Pennsylvania School of Medicine have identified five strategies to reduce unplanned acute care for cancer patients, including leveraging advanced big data analytics, team-based care, and early palliative care. These best practices aim to improve patient experience and reduce hospital utilization.
Research suggests that tiny differences in patient position during radiotherapy can lead to reduced survival chances, particularly when tumours are close to vital organs like the heart. Tightening treatment guidelines could improve survival rates by ensuring more accurate patient positioning.
A combination of XL888, a HSP90 inhibitor, and vemurafenib, a BRAF inhibitor, was found to be safe and effective in treating advanced melanoma patients, with 75% experiencing a response. The treatment resulted in manageable toxicities and durable responses.
A new University of Kansas research effort has resulted in a low-cost, reliable blood test that uses a small plastic chip to deliver diagnostic information similar to bone biopsies. The test has the potential to eliminate the need for invasive bone biopsies and guide treatment for multiple myeloma and other cancers.
A brief bedside visual art intervention (BVAI) improved mood and reduced pain and anxiety in patients with haematological cancers. The study found significant improvements in positive mood and pain scores, as well as decreases in negative mood and anxiety.
A new study suggests that adolescents and young adults with acute leukemia have a survival advantage when receiving treatment at pediatric cancer centers versus adult centers, particularly those affiliated with the National Cancer Institute. This is due to the more experienced care teams in these settings.
A new neuropathy measurement tool has been developed and found effective in quantifying symptoms and treatment efficacy. Minor revisions can improve its validity and universality for adoption in clinics and research settings.
A peer-reviewed study published in Oncotarget found that OncoDNA's comprehensive testing and analysis services, combining multiple biomarkers, increased oncologists' ability to make informed treatment decisions. The study showed a significant improvement in overall survival for late-stage patients, from six months to over 12 months.
The Global ROS1 Initiative is a patient-researcher collaboration that aims to accelerate research on ROS1 cancer. Members have contributed tumor samples and participated in epidemiological surveys, providing valuable insights into the disease.
A new blood test biomarker has been developed to distinguish between benign and malignant lung tumors with 98% accuracy. This breakthrough technology allows healthcare providers to confidently diagnose and treat patients with low-to-moderate risk nodules, reducing the need for invasive procedures.
A study published in Circulation found that patients with acute thrombosis in the leg are at a three-fold higher risk of developing cancer during the first six months after the blood clot. The risk is highest for smoking-related forms of cancer, such as lung and pancreatic cancer.